THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY

Distler O, Maurer B, Vettori S, Blumhardt S, Frey D, Distler A, Beyer C, Distler J (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 75

Pages Range: 66-66

DOI: 10.1136/annrheumdis-2016-eular.5587

Authors with CRIS profile

Christian Beyer Department of Medicine 3 – Rheumatology and Immunology Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

Involved external institutions

Universitätsspital Zürich (USZ) CH Switzerland (CH) Seconda Universita degli Studi di Napoli (SUN) IT Italy (IT)

How to cite

APA:

Distler, O., Maurer, B., Vettori, S., Blumhardt, S., Frey, D., Distler, A.,... Distler, J. (2016). THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY. (pp. 66-66).

MLA:

Distler, O., et al. "THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY." 2016. 66-66.

BibTeX: Download